# EDGAR Filing Document

**Accession Number:** 0001386570
**File Stem:** 0001386570-26-000035
**Filing Date:** 2026-6
**Character Count:** 5560
**Document Hash:** 1f871089531dca77f3f21a1ffd96d59a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001386570-26-000035.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001386570-26-000035

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260624

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260629

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Niagen Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001386570
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262940963
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37752
- **FILM NUMBER:** 261136150

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024
- **BUSINESS PHONE:** 310-388-6706

**MAIL ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ChromaDex Corp.
- **DATE OF NAME CHANGE:** 20080624

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CODY RESOURCES, INC.
- **DATE OF NAME CHANGE:** 20070112

?xml version='1.0' encoding='ASCII'? cdxc-20260624

  

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 24, 2026**

**NIAGEN BIOSCIENCE, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37752** | **26-2940963** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**10900 Wilshire Blvd. Suite 600, Los Angeles, California 90024**

(Address of principal executive offices, including zip code)

**(310) 388-6706**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | NAGE | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Set forth below are the results of the matters submitted for a vote of stockholders at the Company's 2026 Annual Meeting.

*Proposal 1 — Election of directors.* 

The following directors were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until his or her successor is elected, or, if sooner, until such director's death, resignation or removal.

---

| | | | |
|:---|:---|:---|:---|
| **Director Elected** | **For** | **Withheld** | **Broker Non-Votes** |
| Frank L. Jaksch, Jr. | 44531507 | 759870 | 13274979 |
| Robert Fried | 44822825 | 468552 | 13274979 |
| Steven Rubin | 28495147 | 16796230 | 13274979 |
| Wendy Yu | 44520972 | 770405 | 13274979 |
| Gary Ng | 44446052 | 845325 | 13274979 |
| Kristin Patrick | 43608014 | 1683363 | 13274979 |
| Ann Cohen | 44360218 | 931159 | 13274979 |
| Hamed Shahbazi | 30544086 | 14747291 | 13274979 |

---

*Proposal 2 — Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.*

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 56,152,066 | 2,256,090 | 158,200 |  |

---

\* No broker non-votes arose in connection with Proposal 2.

*Proposal 3 — Approval, on an advisory basis, of the compensation paid to the Company's named executive officers.*

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| 43,188,958 | 1,930,441 | 171,978 | 13,274,979 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **NIAGEN BIOSCIENCE, INC.** | **NIAGEN BIOSCIENCE, INC.** |
| Dated: June 29, 2026 | By: | */s/ Ozan Pamir* |
|  |  | Name: Ozan Pamir |
|  |  | Chief Financial Officer |

---